BioMarin gains French approval for Amicus merger

BioMarin Pharmaceutical Inc. reports that France’s Ministry of Economics and Finance has granted foreign direct investment clearance for its planned merger with Amicus Therapeutics.

Rhea-AI Filing Summary

BioMarin Pharmaceutical Inc. reports that France’s Ministry of Economics and Finance has granted foreign direct investment clearance for its planned merger with Amicus Therapeutics. This French FDI clearance satisfies the final outstanding regulatory condition under the Merger Agreement, aside from items to be completed at closing.

The merger, in which Amicus will become a wholly owned subsidiary of BioMarin, is expected to close on April 27, 2026. The companies caution that this timing and other expectations are forward-looking and subject to risks described in their SEC filings and the Amicus merger proxy.

Insights

M&A and regulatory risk analyst

French approval removes a key regulatory hurdle, but closing risks remain.

The update confirms that BioMarin and Amicus have obtained French foreign direct investment clearance, described as the final regulatory condition to their merger other than conditions that are naturally satisfied at closing. This significantly narrows regulatory uncertainty around the transaction.

The companies still frame the merger timing as an expectation, highlighting risks such as completing the merger in the anticipated timeframe, the broader regulatory process, and any related legal proceedings. They direct investors to risk factors in each company’s Form 10-K for the year ended December 31, 2025 and Amicus’ merger proxy statement for more detail.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

French FDI clearance date: April 23, 2026 Expected merger closing date: April 27, 2026

2 metrics

French FDI clearance date April 23, 2026 Date France’s Ministry of Economics and Finance granted Merger clearance

Expected merger closing date April 27, 2026 Anticipated closing date of BioMarin–Amicus merger

Key Terms

Agreement and Plan of Merger, foreign direct investment screening, forward-looking statements, Risk Factors

4 terms

Agreement and Plan of Merger financial

"entered into an Agreement and Plan of Merger (the “Merger Agreement”)"

An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.

foreign direct investment screening regulatory

"granted clearance for the Merger under the French foreign direct investment screening procedures"

forward-looking statements regulatory

"contains forward-looking statements about, among other things, expectations for the date of closing"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Risk Factors financial

"the risk factors contained under the caption “Risk Factors” in BioMarin’s Annual Report"

Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioMarin (BMRN) announce about its merger with Amicus Therapeutics?

BioMarin announced that France’s Ministry of Economics and Finance granted foreign direct investment clearance for its merger with Amicus Therapeutics. This approval satisfies the final regulatory condition under the Merger Agreement, apart from standard conditions that are completed at closing of the transaction.

Why is the French FDI clearance important for the BioMarin (BMRN) and Amicus merger?

The French FDI clearance is described as the final condition to the merger, other than closing-related conditions. Receiving this approval removes a key regulatory hurdle and allows BioMarin and Amicus to move toward completing the transaction, subject to remaining customary steps at closing.

When is the BioMarin–Amicus merger expected to close?

The merger between BioMarin and Amicus is expected to close on April 27, 2026. This date is presented as an expectation and is subject to remaining closing conditions and the various risks and uncertainties detailed in both companies’ SEC filings and Amicus’ merger proxy statement.

What risks do BioMarin (BMRN) and Amicus highlight regarding completion of their merger?

They note risks around consummating the merger in the anticipated timeframe, the time‑consuming and uncertain regulatory process, and any legal proceedings related to the merger. Additional risks are referenced in their Form 10‑K risk factors and Amicus’ merger-related proxy statement filed with the SEC.

Where can investors find more information on the BioMarin–Amicus merger risks?

Investors are referred to risk factors in BioMarin’s and Amicus’ Annual Reports on Form 10‑K for the year ended December 31, 2025. They are also directed to Amicus’ proxy statement on Schedule 14A for the merger, including any amendments or supplements filed with the SEC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 04:20 PM EDT Learn about SEC filing dates

BIOMARIN PHARMACEUTICAL INC NASDAQ false 0001048477 0001048477 2026-04-23 2026-04-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 23, 2026

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware		000-26727		68-0397820
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

770 Lindaro Street		San Rafael		California		94901
(Address of Principal Executive Offices)						(Zip Code)

(415) 506-6700

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		BMRN		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously disclosed, on December 19, 2025, BioMarin Pharmaceutical Inc. (“BioMarin”) and Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin (“Merger Sub”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Amicus Therapeutics, Inc. (“Amicus”), providing for the merger of Merger Sub with and into Amicus (the “Merger”), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin.

On April 23, 2026, the Ministry of Economics and Finance in France granted clearance for the Merger under the French foreign direct investment screening procedures (the “French FDI Clearance”). Under the Merger Agreement, receipt of the French FDI Clearance satisfies the final condition to the Merger other than conditions that by their nature are to be satisfied at the closing of the Merger. The Merger is expected to close on April 27, 2026.

Forward Looking Statements Disclaimer

This Current Report on Form 8-K contains forward-looking statements about, among other things, expectations for the date of closing of the Merger and other statements that are not historical facts. Actual results could differ materially from those anticipated in these forward-looking statements. Except as required by law, each of BioMarin and Amicus assumes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent each of BioMarin’s and Amicus’ current expectations or beliefs concerning various future events that are subject to significant risks and uncertainties, may contain words such as “may,” “will,” “would,” “could,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “project,” “seek,” “should,” “strategy,” “future,” “opportunity,” “potential” or other similar words and expressions indicating future results.

These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including, without limitation, with respect to: consummating the Merger in the anticipated time frame, if at all; the time-consuming and uncertain regulatory approval process; any legal proceedings related to the Merger; and other risks and uncertainties affecting BioMarin and Amicus, including those risk factors detailed in BioMarin’s and Amicus’ filings with the Securities and Exchange Commission, including, without limitation, the risk factors contained under the caption “Risk Factors” in BioMarin’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and Amicus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as such risk factors may be updated by any subsequent reports, as well as the Proxy Statement on Schedule 14A filed by Amicus in connection with the Merger (as amended and/or supplemented). Stockholders of BioMarin and Amicus are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin and Amicus are under no obligation, and expressly disclaim any obligation, to update (publicly or otherwise) or alter any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						BIOMARIN PHARMACEUTICAL INC.,
Date: April 23, 2026				By:		/s/ G. Eric Davis
						G. Eric Davis
						Executive Vice President, Chief Legal Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB